Who is sponsoring NCT06917092?

NCT06917092 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT06917092?

Interventions in NCT06917092: QL1706 combined with chemotherapy ± Bevacizumab.

What condition does NCT06917092 study?

NCT06917092 studies Endometrial Adenocarcinoma, Endometrial Cancer.

Is NCT06917092 still recruiting?

NCT06917092 is currently recruiting now. Last updated 8 April 2025.

Last reviewed 2025-04-08 · How we verify

NCT06917092: QLPPEC/GOG-003

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer

Recruiting now Phase 2 Last updated 8 April 2025

What this trial tests

Phase 2 trial testing QL1706 combined with chemotherapy ± Bevacizumab in Endometrial Adenocarcinoma in 30 participants. Currently enrolling.

Timeline

1 May 2025

Primary endpoint
30 April 2027

30 April 2030

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	30
Start date	1 May 2025
Primary completion	30 April 2027
Estimated completion	30 April 2030
Sites	1 location across China

Drugs / interventions tested

QL1706 combined with chemotherapy ± Bevacizumab — full drug profile →

Conditions studied

Endometrial Adenocarcinoma — all drugs for Endometrial Adenocarcinoma →
Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 70, female only, with Endometrial Adenocarcinoma or Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior anti-PD-1/L1 therapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy in endometrial cancer: mechanisms, clinical evidence, and future directions.
Lian M, Zhang C, Li T, Wang A. · · 2025 · cited 1× · PMID 41583426 · DOI 10.3389/fimmu.2025.1697065
Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors.
Su Z, Zhang X, Xu J, Shen Y. · · 2026 · PMID 41983132 · DOI 10.3389/fimmu.2026.1686568
Predictive biomarkers of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer.
Grau Béjar JF, Yaniz Galende E, Genestie C, Blanc-Durand F, et al · · 2026 · PMID 41835337 · DOI 10.1177/17588359261423888
Dual PD-1 and CTLA-4 targeting in endometrial carcinoma: integrating efficacy, toxicity, and biomarkers into clinical practice
Zhong L, Song L. ·

Verify or expand the search:

Other recruiting trials for Endometrial Adenocarcinoma

Currently open trials in the same condition.

NCT07077876 — Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Tre · recruiting
NCT05824481 — Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer · Phase 2 · active not recruiting
NCT05548296 — A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma · Phase 2 · recruiting
NCT05112601 — Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · Phase 2 · recruiting
NCT05655260 — PErsonalized TReatment for Endometrial Carcinoma · NA · recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06917092 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 8 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06917092.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing